J&J plans significant expansion of global drugs portfolio in coming years

26 June 2018

US health care giant Johnson & Johnson (NYSE: JNJ) plans a significant expansion of a global portfolio of its drugs during the next several years, according to chief scientific officer of the company Paul Stoffells speaking at an exclusive meeting with Russian media.

According to Dr Stoffells, the company currently has about 250 molecules at early stages of development, of which 50 are the subject of clinical trials.

Dr Stoffells said over the past five-10 years, the company has launched on average two drugs onto the market, despite the fact that the number of drugs, which are a subject of clinical trial conducted by the company each year exceeds one hundred.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK